Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01212991 · OUTCOME

Number of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)

A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer · Source last updated 2020-03-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Baseline to discontinuation from the study or death, whichever occurred first (maximum duration of 6.5 years)

What was measured

Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to a maximum duration of 6.5 years that were absent before treatment or that worsened relative to pre-treatment state. Relatedness to study drug was assessed by the investigator.

Analysis population: The safety analysis set included all randomized participants who received at least 1 dose or partial dose of study drug.

Groups in this outcome

Enzalutamide

Participants received enzalutamide 160 mg, administered as four 40-mg capsules, once per day by mouth.

Placebo

Participants received placebo, administered as four capsules, once per day by mouth.

Placebo Participants Crossover to Enzalutamide

Participants who received placebo in double-blind period and who agreed to proceed to open-label phase period, received enzalutamide 160 mg, administered as four 40-mg capsules, once per day by mouth.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Enzalutamide871
Placebo844
Placebo Participants Crossover to Enzalutamide234

Reported measurements

AEs
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Enzalutamide579Not reportedNot reportedNot reportedNot reported
Placebo423Not reportedNot reportedNot reportedNot reported
Placebo Participants Crossover to Enzalutamide119Not reportedNot reportedNot reportedNot reported
SAEs
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Enzalutamide38Not reportedNot reportedNot reportedNot reported
Placebo22Not reportedNot reportedNot reportedNot reported
Placebo Participants Crossover to Enzalutamide14Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        579
      2. group Id
        OG001
        value
        423
      3. group Id
        OG002
        value
        119
    title
    AEs
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        38
      2. group Id
        OG001
        value
        22
      3. group Id
        OG002
        value
        14
    title
    SAEs
denoms
  1. counts
    1. group Id
      OG000
      value
      871
    2. group Id
      OG001
      value
      844
    3. group Id
      OG002
      value
      234
    units
    Participants
description
Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to a maximum duration of 6.5 years that were absent before treatment or that worsened relative to pre-treatment state. Relatedness to study drug was assessed by the investigator.
groups
  1. description
    Participants received enzalutamide 160 mg, administered as four 40-mg capsules, once per day by mouth.
    id
    OG000
    title
    Enzalutamide
  2. description
    Participants received placebo, administered as four capsules, once per day by mouth.
    id
    OG001
    title
    Placebo
  3. description
    Participants who received placebo in double-blind period and who agreed to proceed to open-label phase period, received enzalutamide 160 mg, administered as four 40-mg capsules, once per day by mouth.
    id
    OG002
    title
    Placebo Participants Crossover to Enzalutamide
param Type
COUNT_OF_PARTICIPANTS
population Description
The safety analysis set included all randomized participants who received at least 1 dose or partial dose of study drug.
reporting Status
POSTED
time Frame
Baseline to discontinuation from the study or death, whichever occurred first (maximum duration of 6.5 years)
title
Number of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)
type
OTHER_PRE_SPECIFIED
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice